SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is capturing investor attention as community members debate whether recent volatility is a consolidation phase before a potential run-up driven by the upcoming SpaceX IPO and active military contracts. While some traders express frustration with the recent price pullbacks and sector-wide weakness, others are aggressively accumulating shares, citing long-term defense infrastructure demand and the stock's role as a critical space industry supplier.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is experiencing a sharp sell-off as investors react to AI guidance that fell short of aggressive expectations despite the company reporting record revenue. The community is actively debating whether this represents a long-term AI bubble popping or a prime dip-buying opportunity for a fundamentally strong business.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is experiencing significant volatility driven by intense retail interest and speculative trading following high-profile industry commentary regarding its potential for future growth. The community remains deeply divided, with bulls actively buying the dip to capitalize on anticipated S&P 500 inclusion and AI infrastructure momentum, while bears argue the stock is overextended and driven by hype rather than fundamental performance.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors digest a massive new 270 million dollar cloud infrastructure deal involving Nvidia Blackwell chips, driving significant chatter about its transition into an AI-focused hyperscaler. The community is actively debating the impact of the Northern Data acquisition and record-high short interest, with many anticipating a major squeeze as the company builds out its data center capacity.

LifeVantage Corp. engages in the identification, research, development, formulation, and sale of nutraceutical dietary supplements and personal care products. Its products include Protandim, Axio, TrueScience, PhysIQ, and Petandim. It operates through the Americas, and Asia or Pacific and Europe geographical segments. The company was founded in June 1988 and is headquartered in Lehi, UT.

Lifevantage Corporation

Lifevantage Corporation is currently the focus of significant community interest as investors track a high-conviction short squeeze setup, fueled by extremely high cost-to-borrow fees and limited share availability. Market participants are debating the potential for an explosive upside move as the company's constrained float faces intense short interest pressure.

Ciena Corp. is a network technology company, which engages in the provision of hardware, software, and services to network operators, as well as enabling enhanced network capacity, service delivery, and automation. It operates through the following segments: Networking Platforms, Platform Software and Services, Blue Planet Automation Software and Services, and Global Services. The Networking Platforms segment consists of converged packet optical and packet networking portfolios. The Platform Software and Services segment provides analytics, data, and planning tools to assist customers in managing its networking platforms products. The Blue Planet Automation Software and Services segment enables customers to implement large-scale software and IT-led OSS transformations by transforming legacy networks into service ready networks. The Global Services segment offers a broad suite of value-added services. The company was founded by Patrick H. Nettles and Kevin Brian Kimberlin in 1992 and is headquartered in Hanover, MD.

CIENA Corp.

Ciena is experiencing significant trading activity as market participants closely monitor its role in the critical AI infrastructure buildout. The community remains divided, with some investors focusing on strong earnings and a massive backlog as catalysts for long-term growth, while others express concerns over valuation and the potential for increased volatility.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is attracting significant attention as investors shift focus toward its role in QNX technology and physical AI, leading to high-volume trading and intense community debate over whether recent price volatility represents a healthy consolidation or a speculative bubble. While the stock faces broader market pressure, long-term proponents remain fixated on upcoming earnings and potential design-win catalysts, urging shareholders to ignore short-term price swings and focus on the company's evolving growth narrative.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is seeing heightened investor interest and increased volatility following the launch of an aggressive $250 billion U.S. connectivity infrastructure investment plan. The community is actively debating the stock's long-term value and dividend reliability against the backdrop of broader sector consolidation and intense competition from satellite-based rivals.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing a surge in institutional accumulation and community optimism, driven by promising clinical data, a shrinking float, and high expectations for upcoming BLA submissions. The community is actively discussing the potential for a transformative oncology buyout, with investors highlighting institutional confidence, significant short interest, and upcoming catalysts as key drivers for near-term momentum.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is currently trending as investors debate the stock's long-term potential versus its frustratingly slow price movement within a multi-year trading range. While the community remains divided over management's performance and recent capital-raising decisions, many are focused on the company's robust pipeline and upcoming clinical data readouts as the primary catalysts for a potential breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NXST $LLY $BMY $BSX 
 
TOP 5 WEEKEND STORIES: 
 
1) Colorado Attorney General Phil Weiser announced on X Friday night that the judge in the state&#39;s case challenging the Nexstar (NXST) - Tegna merger issued a temporary restraining order, blocking the companies from merging. On April 7, the judge will consider the request to bar the merger &quot;while we make our case to stop it permanently,&quot; Weiser added. U.S. District Judge Troy Nunley sided with DirecTV, which claimed that Nexstar&#39;s acquisition of Tegna would &quot;drive up the price it can extract from DirecTV and other distributors,&quot; bring layoffs and reduce competition. DirecTV established &quot;a likelihood of success on the merits&quot; on its claim, and that moving forward with the transaction would create &quot;irreparable harm,&quot; the judge wrote. Eight states sued to block the merger in a separate filing on the same day as DirecTV&#39;s.  
 
2) Insilico Medicine announced a drug discovery collaboration with Eli Lilly and Company (LLY) that uses Insilico&#39;s AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. The agreement grants Lilly an exclusive worldwide license for the development, manufacturing, and commercialization of potentially best-in-class, novel oral therapeutics in preclinical development for certain indications. In addition, Insilico and Lilly will collaborate on multiple R&amp;D programs focused on targets selected by Lilly, by combining Insilico&#39;s state-of-the-art Pharma.AI platforms with Lilly&#39;s development capabilities and deep disease-area expertise. Under the terms of the agreement, Insilico is eligible to receive an $115 million upfront payment, followed by development, regulatory, and commercial milestones that could bring the total deal value to approximately $2.75 billion, plus tiered royalties on future sales.  
 
3) Bristol Myers Squibb (BMY) announced positive data from the Phase 3 Scout-HCM trial of Camzyos, the first study of a cardiac myosin inhibitor in adolescents with symptomatic obstructive hypertrophic cardiomyopathy. The Scout-HCM trial met its primary endpoint, demonstrating a clinically meaningful and statistically significant reduction from baseline in Valsalva left ventricular outflow tract gradient at Week 28 with Camzyos versus placebo.  
 
4) Eli Lilly and Company announced detailed results from the Together-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz and Zepbound compared to Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one additional weight-related comorbid condition. At the primary endpoint of 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all key secondary endpoints for statistically significant superiority to Taltz monotherapy.  
 
5) Boston Scientific (BSX) announced that the Champion-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the Watchman FLX Left Atrial Appendage Closure, LAAC, Device compared to non-vitamin K antagonist oral anticoagulants, NOACs, as a first-line option for stroke risk reduction in a broad population of patients with non-valvular atrial fibrillation, NVAF. At 36 months: The primary safety endpoint was met with data demonstrating the WATCHMAN FLX device was statistically superior to NOACs for non-procedural major and clinically relevant non-major bleeding, achieving a 45% relative reduction in non-procedural bleeding risk.

StockTwits Web

Nexstar Media Group Inc - Ordinary Shares - Class A

Lilly(Eli) & Co

Bristol-Myers Squibb Co.

Boston Scientific Corp.

 
 
TOP 5 WEEKEND STORIES: 
 
1) Colorado Attorney General Phil Weiser announced on X Friday night that the judge in the state's case challenging the Nexstar (NXST) - Tegna merger issued a temporary restraining order, blocking the companies from merging. On April 7, the judge will consider the request to bar the merger "while we make our case to stop it permanently," Weiser added. U.S. District Judge Troy Nunley sided with DirecTV, which claimed that Nexstar's acquisition of Tegna would "drive up the price it can extract from DirecTV and other distributors," bring layoffs and reduce competition. DirecTV established "a likelihood of success on the merits" on its claim, and that moving forward with the transaction would create "irreparable harm," the judge wrote. Eight states sued to block the merger in a separate filing on the same day as DirecTV's.  
 
2) Insilico Medicine announced a drug discovery collaboration with Eli Lilly and Company (LLY) that uses Insilico's AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. The agreement grants Lilly an exclusive worldwide license for the development, manufacturing, and commercialization of potentially best-in-class, novel oral therapeutics in preclinical development for certain indications. In addition, Insilico and Lilly will collaborate on multiple R&D programs focused on targets selected by Lilly, by combining Insilico's state-of-the-art Pharma.AI platforms with Lilly's development capabilities and deep disease-area expertise. Under the terms of the agreement, Insilico is eligible to receive an $115 million upfront payment, followed by development, regulatory, and commercial milestones that could bring the total deal value to approximately $2.75 billion, plus tiered royalties on future sales.  
 
3) Bristol Myers Squibb (BMY) announced positive data from the Phase 3 Scout-HCM trial of Camzyos, the first study of a cardiac myosin inhibitor in adolescents with symptomatic obstructive hypertrophic cardiomyopathy. The Scout-HCM trial met its primary endpoint, demonstrating a clinically meaningful and statistically significant reduction from baseline in Valsalva left ventricular outflow tract gradient at Week 28 with Camzyos versus placebo.  
 
4) Eli Lilly and Company announced detailed results from the Together-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz and Zepbound compared to Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one additional weight-related comorbid condition. At the primary endpoint of 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all key secondary endpoints for statistically significant superiority to Taltz monotherapy.  
 
5) Boston Scientific (BSX) announced that the Champion-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the Watchman FLX Left Atrial Appendage Closure, LAAC, Device compared to non-vitamin K antagonist oral anticoagulants, NOACs, as a first-line option for stroke risk reduction in a broad population of patients with non-valvular atrial fibrillation, NVAF. At 36 months: The primary safety endpoint was met with data demonstrating the WATCHMAN FLX device was statistically superior to NOACs for non-procedural major and clinically relevant non-major bleeding, achieving a 45% relative reduction in non-procedural bleeding risk.